SECURITIES AND EXCHANGE COMMISSION
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: March 28, 2003
(Date of earliest event reported)
REGENERON PHARMACEUTICALS, INC.
(State or Other Jurisdiction of
(Commission File Number)
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
(Address of principal executive offices, including zip code)
Registrants telephone number, including area code: (914) 347-7000
ITEM 5. OTHER EVENTS
On March 28, 2003, the Company issued a press release announcing its Collaboration, License and Option Agreement with Novartis Pharma AG, a copy of which is attached to this filing.
On March 31, 2003, the Company issued a press release announcing the results of its Phase III obesity study. This release as issued contained a statement that AXOKINE treatment achieved statistically significant results in all secondary endpoints of the study. A corrected press release is attached to this filing, which clarifies that AXOKINE treatment achieved statistically significant results in two of the three secondary endpoints.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
|99a||Press Release dated March 28, 2003|
|99b||Press Release dated March 31, 2003 (As Corrected)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|REGENERON PHARMACEUTICALS, INC.|
|By:||/s/ Stuart Kolinski|
|Name: Stuart Kolinski
Title: Vice President & General Counsel
|Date: April 1, 2003|